Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | EVP, Head of Discovery Chem | July 02, 2021 | July 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 02, 2021 · Filed July 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,933 |
Reported balance
After 2021-07-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-02 · Grant · Acquired 7,853 · Balance 101,933 F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Wenqing Yao's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | Direct | 98,980 |
Reported balance
After 2021-07-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-07-02 · Tax withholding · Disposed 2,953 · Balance 98,980 F2: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. |
| Common StockSEC Table I · non-derivative | Direct | 98,575 |
Reported balance
After 2021-07-06 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2021-07-06 · Tax withholding · Disposed 405 · Balance 98,575 F2: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F3: Including the July 2, 2021 Restricted Stock Unit Grant, this includes an aggregate of 58,773 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.58 · Expires 2031-07-01 | Direct | 15,054 |
Reported balance
After 2021-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-02 · Grant · Acquired 15,054 · Balance 15,054 F4: Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Wenqing Yao's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock.
F3: Including the July 2, 2021 Restricted Stock Unit Grant, this includes an aggregate of 58,773 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.
F4: Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2021 Filed Jul 7, 2021 21:54 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 405 | $83.34 | $33,752.70 |
DisclosureSEC source: 0001209191-21-045892 · doc4.xml · nonDerivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,575 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2021 Restricted Stock Unit Grant, this includes an aggregate of 58,773 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 21:54 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $83.58 | $0.00 |
DisclosureSEC source: 0001209191-21-045892 · doc4.xml · derivative · entry 4 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2031-07-01 F4 · derivative.exercise_date: Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 21:54 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,953 | $83.58 | $246,811.74 |
DisclosureSEC source: 0001209191-21-045892 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,980 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 21:54 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 7,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045892 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,933 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Wenqing Yao's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:11 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 27,194 | $85.37 | $2,321,551.78 |
DisclosureSEC source: 0001209191-21-043975 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,080 F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · shares: Represents weighted average sale price. Actual sale prices ranged from $84.81 - $85.90. F4 · shares: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F5 · balance_after: This includes an aggregate of 58,222 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:11 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 22,806 | $85.61 | $1,952,421.66 |
DisclosureSEC source: 0001209191-21-043975 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,274 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:32 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 19,986 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-21-005731 · doc4.xml · derivative · entry 6 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,986 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:32 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,559 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-21-005731 · doc4.xml · derivative · entry 5 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,559 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:32 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 19,986 | $100.00 | $1,998,600.00 |
DisclosureSEC source: 0001209191-21-005731 · doc4.xml · nonDerivative · entry 4 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,784 F2 · balance_after: This includes an aggregate of 108,222 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:32 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 19,986 | $73.21 | $1,463,175.06 |
DisclosureSEC source: 0001209191-21-005731 · doc4.xml · nonDerivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:32 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,559 | $100.00 | $155,900.00 |
DisclosureSEC source: 0001209191-21-005731 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,784 Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:32 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,559 | $73.21 | $114,134.39 |
DisclosureSEC source: 0001209191-21-005731 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:40 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004418 · doc4.xml · derivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F4 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:40 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 11,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004418 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,784 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Wenqing Yao's continued service with the Issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 15, 2020 Restricted Stock Unit Grant, this includes an aggregate of 108,222 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. F3 · balance_after: This total excludes 24,589 shares that were erroneously reported as being owned by the reporting person in the reporting persons Form 4 filed on June 22, 2020 and three Forms 4 filed by the reporting person after that date. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 22:03 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059167 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,851 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 96,700 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:31 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 639 | $104.25 | $66,615.75 |
DisclosureSEC source: 0001209191-20-042855 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,619 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 95,468 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,648 | $0.00 Strike: $64.55 | $0.00 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · derivative · entry 10 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,648 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 905 | $0.00 Strike: $64.55 | $0.00 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · derivative · entry 9 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 905 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 15,648 | $107.32 | $1,679,343.36 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · nonDerivative · entry 7 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,258 F6 · balance_after: Including the July 2, 2020 Restricted Stock Unit Grant, this includes an aggregate of 96,857 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 15,648 | $64.55 | $1,010,078.40 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · nonDerivative · entry 6 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $105.66 - $108.48 F5 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 905 | $107.32 | $97,124.60 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · nonDerivative · entry 5 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,258 Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 905 | $64.55 | $58,417.75 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · nonDerivative · entry 4 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $105.66 - $108.48 F5 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 404 | $107.79 | $43,547.16 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · nonDerivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,258 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $106.47 | $0.00 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · derivative · entry 8 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2030-07-01 F7 · derivative.exercise_date: Beginning July 2, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,187 | $106.47 | $232,849.89 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,662 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:30 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-041572 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,849 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Wenqing Yao's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:29 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-038189 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,188 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on June 18, 2020. The performance shares will vest in full on June 28, 2022, subject to the Reporting Person's continued service with the Issuer through the vesting date. Each performance share initially represented the right to receive one share of common stock based on, and subject to, the approval of a new chemical entity developed by the issuer as a drug by the U.S. FDA or the European Medicines Agency during a specified performance period. F2 · balance_after: Includes an aggregate of 95,832 shares of common stock issuable pursuant to the performance shares reported above and previously reported restricted stock units and performance shares that have not vested as of June 18, 2020. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:22 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010112 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,189 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 13, 2020. The performance shares vest 25% annually over four years from the grant date of July 2, 2019, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 125% of the number of performance shares awarded, and the performance criteria was achieved at the 101.80% level. F2 · balance_after: Including the Performance Stock Units earned on February 13, 2020, this includes an aggregate of 70,832 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:48 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,542 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-20-007561 · doc4.xml · derivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,542 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:48 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 17,542 | $75.97 | $1,332,665.74 |
DisclosureSEC source: 0001209191-20-007561 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,308 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $74.56 - $76.46 F4 · balance_after: This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:48 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 17,542 | $18.32 | $321,369.44 |
DisclosureSEC source: 0001209191-20-007561 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:16 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004455 · doc4.xml · derivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:32 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,835 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-058714 · doc4.xml · derivative · entry 6 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,542 Underlying: Common Stock · 16,835 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:32 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 16,835 | $95.00 | $1,599,325.00 |
DisclosureSEC source: 0001209191-19-058714 · doc4.xml · nonDerivative · entry 4 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,308 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:32 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 16,835 | $18.32 | $308,417.20 |
DisclosureSEC source: 0001209191-19-058714 · doc4.xml · nonDerivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:32 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,165 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-058714 · doc4.xml · derivative · entry 5 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,377 Underlying: Common Stock · 3,165 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:32 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 3,165 | $95.00 | $300,675.00 |
DisclosureSEC source: 0001209191-19-058714 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,308 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:32 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 3,165 | $18.32 | $57,982.80 |
DisclosureSEC source: 0001209191-19-058714 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:11 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-058098 · doc4.xml · derivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,542 Underlying: Common Stock · 15,000 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:11 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 15,000 | $90.00 | $1,350,000.00 |
DisclosureSEC source: 0001209191-19-058098 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,308 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:11 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 15,000 | $18.32 | $274,800.00 |
DisclosureSEC source: 0001209191-19-058098 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 22:23 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,960 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-055288 · doc4.xml · derivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,542 Underlying: Common Stock · 7,960 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 22:23 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 7,960 | $85.00 | $676,600.00 |
DisclosureSEC source: 0001209191-19-055288 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,308 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 22:23 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 7,960 | $18.32 | $145,827.20 |
DisclosureSEC source: 0001209191-19-055288 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 20:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-054622 · doc4.xml · nonDerivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,308 F2 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on October 30, 2019. The performance shares vest 100% on the third anniversary of the grant date of June 28, 2018, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of certain clinical milestones determined by the Issuer's Compensation Committee in October 2019 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 100% of the number of performance shares awarded, and the performance criteria was achieved at the 100% level. F3 · balance_after: This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,040 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-054622 · doc4.xml · derivative · entry 4 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,502 Underlying: Common Stock · 2,040 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 20:10 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 2,040 | $85.00 | $173,400.00 |
DisclosureSEC source: 0001209191-19-054622 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,308 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 2,040 | $18.32 | $37,372.80 |
DisclosureSEC source: 0001209191-19-054622 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 20:57 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 639 | $81.39 | $52,008.21 |
DisclosureSEC source: 0001209191-19-042183 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,308 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 404 | $85.28 | $34,453.12 |
DisclosureSEC source: 0001209191-19-041584 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,947 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 15,340 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.